An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling

Oncogene

Volumn 31, Issue 10, 2012, Pages 1275-1286

  Sala, G ^a,b   Traini, S ^a,b   D'Egidio, M ^a,b   Vianale, G ^b   Rossi, C ^b   Piccolo, E ^a,b   Lattanzio, R ^b   Piantelli, M ^a,b   Tinari, N ^a,b   Natali, P G ^a   Muraro, R ^a,b   Iacobelli, S ^a,b  

^a MediaPharma Srl   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

ErbB 3 receptor; ErbB 3 Akt pathway; monoclonal antibody; targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MP RM 1; NEU DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL LINE; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; LIGANDS; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84858006197     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.322     Document Type: Article

References (48)

1. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA et al. (1995). Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821.
2. Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S et al. (2005). Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 24: 4540-4548. (Pubitemid 41032617)
3. Baselga J, Swain SM. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475.
4. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. (1996). All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271: 5251-5257. (Pubitemid 26075021)
5. Bianchi S, Palli D, Falchetti M, Saieva C, Masala G, Mancini B et al. (2006). ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J Cell Physiol 206: 702-708. (Pubitemid 43191045)
6. Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG et al. (2010). Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res 70: 5994-6003.
7. Citri A, Yarden Y. (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516. (Pubitemid 44036456)
8. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR et al. (1987a). Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51: 1063-1070.
9. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. (1987b). erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178-182. (Pubitemid 17095921)
10. Digiesi G, Giacomini P, Fraioli R, Mariani M, Nicotra MR, Segatto O et al. (1992). Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2. Hybridoma 11: 519-527.
11. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. (Pubitemid 46799492)
12. Fiorini M, Ballaro C, Sala G, Falcone G, Alema S, Segatto O. (2002). Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene 21: 6530-6539. (Pubitemid 35155457)
13. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317-328. (Pubitemid 38482068)
14. Giampaglia M, Chiuri VE, Tinelli A, De Laurentiis M, Silvestris N, Lorusso V. (2010). Lapatinib in breast cancer: clinical experiences and future perspectives. Cancer Treat Rev 36(Suppl 3): S72-S79.
15. Gschwind A, Fischer OM, Ullrich A. (2004). The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4: 361-370. (Pubitemid 38579482)
16. Hynes NE, Lane HA. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354. (Pubitemid 40637826)
17. Hynes NE. (2007). Targeting ERBB receptors in cancer. Recent Results Cancer Res 172: 45-57.
18. Hynes NE, MacDonald G. (2009). ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184.
19. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S et al. (2005). Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 65: 9176-9184. (Pubitemid 41507981)
20. Karamouzis MV, Badra FA, Papavassiliou AG. (2007). Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 39: 851-856. (Pubitemid 46575320)
21. Kraus MH, Fedi P, Starks V, Muraro R, Aaronson SA. (1993). Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci USA 90: 2900-2904. (Pubitemid 23113525)
22. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP et al. (2008). A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68: 5878-5887.
23. Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G et al. (1996). Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice. J Natl Cancer Inst 88: 419-429.
24. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. (2007). Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 120: 1874-1882. (Pubitemid 46418362)
25. Mendelsohn J, Baselga J. (2006). Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385. (Pubitemid 44142736)
26. Mottolese M, Venturo I, Donnorso RP, Curcio CG, Rinaldi M, Natali PG. (1988). Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin. Eur J Cancer Clin Oncol 24: 1277-1284.
27. Natali PG, Nicotra MR, Di Renzo MF, Prat M, Bigotti A, Cavaliere R et al. (1993). Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 68: 746-750. (Pubitemid 23301281)
28. Piccolo E, Innominato PF, Mariggio MA, Maffucci T, Iacobelli S, Falasca M. (2002). The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene 21: 6520-6529. (Pubitemid 35155456)
29. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ. (1998). Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4: 2957-2966. (Pubitemid 29001467)
30. Prigent SA, Gullick WJ. (1994). Identification of c-erbB-3 binding sites for phosphatidylinositol 30-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 13: 2831-2841.
31. Rege-Cambrin G, Scaravaglio P, Carozzi F, Giordano S, Ponzetto C, Comoglio PM et al. (1992). Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genet Cytogenet 64: 170-173. (Pubitemid 23044958)
32. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M et al. (2008). HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14: 5188-5197.
33. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684. (Pubitemid 41464706)
34. Sala G, Dituri F, Raimondi C, Previdi S, Maffucci T, Mazzoletti M et al. (2008). Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res 68: 10187-10196.
35. Saxena R, Dwivedi A. (2010). ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Med Res Rev (e-pub ahead of print).
36. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M et al. (2010). An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 70: 2485-2494.
37. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L et al. (2009). Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2: ra31.
38. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441. (Pubitemid 46160912)
39. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. (2010). ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 107: 7692-7697.
40. Sithanandam G, Fornwald LW, Fields J, Anderson LM. (2005). Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene 24: 1847-1859. (Pubitemid 40462787)
41. Sunada H, Magun BE, Mendelsohn J, MacLeod CL. (1986). Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83: 3825-3829. (Pubitemid 16062376)
42. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M et al. (2006). ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24: 4317-4323. (Pubitemid 46630790)
43. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. (1995). Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267-4275.
44. Weinstein JN, van Osdol W. (1992). Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the 'binding site barrier'. Cancer Res 52: 2747s-2751s.
45. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. (2003). Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200: 290-297. (Pubitemid 36827302)
46. Wu WK, Tse TT, Sung JJ, Li ZJ, Yu L, Cho CH. (2009). Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. Anticancer Res 29: 229-234.
47. Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M et al. (1997). High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 10: 142-148. (Pubitemid 27110039)
48. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E et al. (2006). Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10: 39-50. (Pubitemid 44018087)